Intervacc

Intervacc AB (publ) today announces that the variation application previously submitted to the U.K's Veterinary Medicines Directorate, (VMD), has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for Strangvac®, the company's vaccine against equine strangles.

As previously announced, the EMA has approved the corresponding variation application, and together these two approvals mark an important milestone in Intervacc's efforts to ensure increased flexibility and stability in production processes.

"That we have now received approvals for our improved methods and processes from both the VMD and the EMA is a significant milestone for Intervacc," says Jonas Sohlman, CEO of Intervacc.

The improved processes have already been implemented in the production carried out during the autumn, and new vials has been made available for sale through a special procedure, Special Batch Release, in markets where it has been launched.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on March 28, 2025, 15.15 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins. The Intervacc share is on listed the Nasdaq First North Growth Market.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10